Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25628939 | 0.83 | PTGS2 (0.40) | PTGS2PTGS1PLK4HSD11B1AKR1C3 | |
| SCHEMBL10051059 | 0.83 | CA1 (0.55) | CA1CA2ENPP2 | |
| SCHEMBL24110499 | 0.83 | CA12 (0.43) | CA12CA1CA2CA9NFE2L2 | |
| SCHEMBL775608 | 0.81 | HTR2C (0.59) | CA12CA1CA2CA9NFE2L2 | |
| SCHEMBL24950155 | 0.81 | ACHE (0.48) | CA12CA1CA2CA9NFE2L2 | |
| SCHEMBL15514618 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9NFE2L2 | |
| SCHEMBL1889098 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9NFE2L2 | |
| SCHEMBL777610 | 0.78 | PSIP1 (0.56) | CA12CA1CA2CA9NFE2L2 | |
| SCHEMBL5831675 | 0.78 | PTGS2 (0.56) | PTGS2PTGS1PLK4SCD | |
| SCHEMBL67448 | 0.77 | ALDH1A1 (0.52) | CA12CA1CA2CA9NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104409772-B | Lithium-ion battery electrolyte and lithium-ion battery | 张家港市国泰华荣化工新材料有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-104531397-A | Cleaning solution for sheet glass substrate thinning pre-cleaning, and application thereof | HUIJING DISPLAY TECHNOLOGY SUZHOU CO LTD | 2015-04-22 | — | — | CN | claimed |
| CN-104409772-A | Lithium-ion battery electrolyte and lithium-ion battery | ZHANGJIAGANG GUOTAI HUARONG NEW CHEMICAL MATERIALS | 2015-03-11 | — | — | CN | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| CN-118164961-A | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-111393414-B | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| CN-1926127-A | Novel 2-heteroaryl substituted benzimidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-03-07 | — | — | CN | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1867554-A | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | PTGS2 465/4885PTGS1 581/4885PLK4 1633/4885 |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | PTGS2 559/4885PTGS1 427/4885PLK4 4724/4885 |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, XDH, CYP3A43 | PTGS2 2313/4885PTGS1 1679/4885PLK4 4441/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | PTGS2 4370/4885PTGS1 3755/4885PLK4 1073/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | PTGS2 296/4885PTGS1 137/4885PLK4 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.